Riskpilot← Back to searchSign inGet full accessSegrén Flow Cytometry Support AB
ABIn liquidationOrg 5568519747UmeåOther education n.e.c. · NACE 8559Est. 20111 employees
Revenue 2024
SEK 0
EBITDA margin
—
-46% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -11K
-73% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -13K | -46% |
| Net profit | SEK -11K | -73% |
| Total assets | SEK 129K | -14% |
| Equity | SEK 129K | -8% |
| Employees | 1 | — |
Legal name
Segrén Flow Cytometry Support AB
Org number
5568519747
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
6 maj 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Aktiebolaget ska bedriva agentur-, konsult- och utbildnings- verksamhet inom området biomedicinsk cellanalys och cellsortering och därmed förenlig verksamhet.
Address
Umeå
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 360 | 125 | 492 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | −0 | — | — |
| EBITDA | −71 | −31 | 37 | −60 | 220 | −85 | −12 | −9 | −13 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | −71 | −31 | 37 | −60 | 220 | −85 | −12 | −9 | −13 |
| Net financials | — | — | — | — | — | — | 0 | 3 | 2 |
| Profit before tax | −30 | −31 | 37 | −60 | 220 | −85 | −12 | −6 | −11 |
| Tax | −0 | −0 | −0 | −0 | −30 | −0 | — | — | — |
| Net profit | −30 | −31 | 37 | −60 | 190 | −85 | −12 | −6 | −11 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 217 | 149 | 276 | 92 | 398 | 184 | 156 | 150 | 129 |
| Equity | 108 | 77 | 114 | 54 | 244 | 159 | 146 | 140 | 129 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Short-term debt | 109 | 73 | 162 | 38 | 154 | 25 | 9 | 10 | 0 |
| Total debt | 109 | 73 | 162 | 38 | 154 | 25 | 9 | 10 | — |
EBITDA margin
-1315400.0%
This company
15.8%
Market median
-8325416% vs market
20162024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20162024
Return on equity
-8.6%
This company
18.4%
Market median
-147% vs market
20162024
Net profit margin
-1102500.0%
This company
8.1%
Market median
-13611211% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EF External Signatory | External Signatory | 2024 | — | — |
MV External Signatory | External Signatory | 2024 | — | — |
AB External Signatory | External Signatory | 2024 | — | — |
AE Liquidator | Liquidator | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Segrén Flow Cytometry Support AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Frida Ramona Melander Vängbo | External Signatory | 0 companies |
| Mona Veronica Vesterberg | External Signatory | 0 companies |
| Anna Birgitta Emanuelsson | External Signatory | 0 companies |
| Anna Elisabeth Adolfsson | Liquidator | 0 companies |
| Agneta Susanne Segrén | Deputy Board Member | 0 companies |
| Tor Sverker Segrén | Board of Directors | 0 companies |